Progress in defining multidrug resistance in leukemia

J. Kappelmayer, A. Simon, Flóra Kiss, Zsuzsa Hevessy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Multidrug resistance (MDR) is a naturally occurring defense phenomenon by which cells battle against chemically foreign substances (xenobiotics), including some cytotoxic drugs. Membrane transporter hyperactivity is a major contributor to MDR and is the primary target of both diagnostic and therapeutic interventions. Multi-xenobiotic resistance can be exploited as several fluorescent indicator probes are extruded by the same drug transporters, making it possible to quantitatively measure MDR activity in cell lines and clinical samples by flow cytometry. The literature on MDR is reported in a number of different formats, making it difficult to compare data from various groups. This article will briefly review the pothomechanism, then focus upon the diagnostic approach, the interpretation of results from clinical samples and correlations with other variables. The authors believe that a standardized MDR assay, as well as a suitable monitoring test, may become a prognostic marker in several types of leukemia.

Original languageEnglish
Pages (from-to)209-217
Number of pages9
JournalExpert Review of Molecular Diagnostics
Volume4
Issue number2
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Multiple Drug Resistance
Leukemia
Xenobiotics
Membrane Transport Proteins
Fluorescent Dyes
Pharmaceutical Preparations
Flow Cytometry
Cell Line

Keywords

  • Calcein
  • Drug resistance
  • Flow cytometry
  • P-glycoprotein
  • Verapimil

ASJC Scopus subject areas

  • Genetics

Cite this

Progress in defining multidrug resistance in leukemia. / Kappelmayer, J.; Simon, A.; Kiss, Flóra; Hevessy, Zsuzsa.

In: Expert Review of Molecular Diagnostics, Vol. 4, No. 2, 03.2004, p. 209-217.

Research output: Contribution to journalArticle

Kappelmayer, J. ; Simon, A. ; Kiss, Flóra ; Hevessy, Zsuzsa. / Progress in defining multidrug resistance in leukemia. In: Expert Review of Molecular Diagnostics. 2004 ; Vol. 4, No. 2. pp. 209-217.
@article{d0213c0cbd474c70a473f9b7e1c997f9,
title = "Progress in defining multidrug resistance in leukemia",
abstract = "Multidrug resistance (MDR) is a naturally occurring defense phenomenon by which cells battle against chemically foreign substances (xenobiotics), including some cytotoxic drugs. Membrane transporter hyperactivity is a major contributor to MDR and is the primary target of both diagnostic and therapeutic interventions. Multi-xenobiotic resistance can be exploited as several fluorescent indicator probes are extruded by the same drug transporters, making it possible to quantitatively measure MDR activity in cell lines and clinical samples by flow cytometry. The literature on MDR is reported in a number of different formats, making it difficult to compare data from various groups. This article will briefly review the pothomechanism, then focus upon the diagnostic approach, the interpretation of results from clinical samples and correlations with other variables. The authors believe that a standardized MDR assay, as well as a suitable monitoring test, may become a prognostic marker in several types of leukemia.",
keywords = "Calcein, Drug resistance, Flow cytometry, P-glycoprotein, Verapimil",
author = "J. Kappelmayer and A. Simon and Fl{\'o}ra Kiss and Zsuzsa Hevessy",
year = "2004",
month = "3",
doi = "10.1586/14737159.4.2.209",
language = "English",
volume = "4",
pages = "209--217",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Progress in defining multidrug resistance in leukemia

AU - Kappelmayer, J.

AU - Simon, A.

AU - Kiss, Flóra

AU - Hevessy, Zsuzsa

PY - 2004/3

Y1 - 2004/3

N2 - Multidrug resistance (MDR) is a naturally occurring defense phenomenon by which cells battle against chemically foreign substances (xenobiotics), including some cytotoxic drugs. Membrane transporter hyperactivity is a major contributor to MDR and is the primary target of both diagnostic and therapeutic interventions. Multi-xenobiotic resistance can be exploited as several fluorescent indicator probes are extruded by the same drug transporters, making it possible to quantitatively measure MDR activity in cell lines and clinical samples by flow cytometry. The literature on MDR is reported in a number of different formats, making it difficult to compare data from various groups. This article will briefly review the pothomechanism, then focus upon the diagnostic approach, the interpretation of results from clinical samples and correlations with other variables. The authors believe that a standardized MDR assay, as well as a suitable monitoring test, may become a prognostic marker in several types of leukemia.

AB - Multidrug resistance (MDR) is a naturally occurring defense phenomenon by which cells battle against chemically foreign substances (xenobiotics), including some cytotoxic drugs. Membrane transporter hyperactivity is a major contributor to MDR and is the primary target of both diagnostic and therapeutic interventions. Multi-xenobiotic resistance can be exploited as several fluorescent indicator probes are extruded by the same drug transporters, making it possible to quantitatively measure MDR activity in cell lines and clinical samples by flow cytometry. The literature on MDR is reported in a number of different formats, making it difficult to compare data from various groups. This article will briefly review the pothomechanism, then focus upon the diagnostic approach, the interpretation of results from clinical samples and correlations with other variables. The authors believe that a standardized MDR assay, as well as a suitable monitoring test, may become a prognostic marker in several types of leukemia.

KW - Calcein

KW - Drug resistance

KW - Flow cytometry

KW - P-glycoprotein

KW - Verapimil

UR - http://www.scopus.com/inward/record.url?scp=1542268291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542268291&partnerID=8YFLogxK

U2 - 10.1586/14737159.4.2.209

DO - 10.1586/14737159.4.2.209

M3 - Article

C2 - 14995907

AN - SCOPUS:1542268291

VL - 4

SP - 209

EP - 217

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -